Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.146 EUR | -0.35% |
|
-1.72% | -36.40% |
06-14 | Abionyx: positive response from FDA, share price rises | CF |
06-13 | ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis | CI |
Sales 2024 * | 4.6M 4.92M 6.72M | Sales 2025 * | 7.1M 7.6M 10.38M | Capitalization | 38.13M 40.79M 55.74M |
---|---|---|---|---|---|
Net income 2024 * | -6M -6.42M -8.77M | Net income 2025 * | -9M -9.63M -13.16M | EV / Sales 2024 * | 7.9 x |
Net cash position 2024 * | 1.8M 1.93M 2.63M | Net Debt 2025 * | 200K 214K 292K | EV / Sales 2025 * | 5.4 x |
P/E ratio 2024 * |
-6.96
x | P/E ratio 2025 * |
-5.64
x | Employees | 61 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.01% |
1 day | -0.35% | ||
1 week | -1.72% | ||
Current month | +8.11% | ||
1 month | -1.72% | ||
3 months | +8.11% | ||
6 months | +10.19% | ||
Current year | -36.40% |
![Extreme 1.132](/images/extremecours_fleche.png)
![Extreme 1.132](/images/extremecours_fleche.png)
![Extreme 0.947](/images/extremecours_fleche.png)
![Extreme 0.947](/images/extremecours_fleche.png)
![Extreme 0.891](/images/extremecours_fleche.png)
![Extreme 0.1766](/images/extremecours_fleche.png)
![Extreme 0.1766](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-26 | 1.146 | -0.35% | 0 |
Delayed Quote Börse Stuttgart, June 26, 2024 at 04:30 am
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.45% | 122B | |
+21.96% | 116B | |
+25.36% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-15.94% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- ABNX Stock
- 609 Stock